Όλο το DSpace

Πλοήγηση ανά Θέμα "Antineoplastic Combined Chemotherapy Protocols"

Αποτελέσματα 1-11 από 11

    • Dynamic changes of CTCs in patients with metastatic HR(+)/HER2(−) breast cancer receiving salvage treatment with everolimus/exemestane 

      Spiliotaki M., Kallergi G., Nikolaou C., Xenidis N., Politaki E., Apostolaki S., Georgoulia N., Koinis F., Tsoukalas N., Hatzidaki D., Kotsakis A., Georgoulias V. (2021)
      Purpose: Detection of CTCs represents a poor prognostic factor in patients with early and metastatic breast cancer (mBC) and treatment with everolimus–exemestane (E/E) is an established effective treatment in hormone ...

    • Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes 

      Kotoula V., Karavasilis V., Zagouri F., Kouvatseas G., Giannoulatou E., Gogas H., Lakis S., Pentheroudakis G., Bobos M., Papadopoulou K., Tsolaki E., Pectasides D., Lazaridis G., Koutras A., Aravantinos G., Christodoulou C., Papakostas P., Markopoulos C., Zografos G., Papandreou C., Fountzilas G. (2016)
      The purpose of this study is to investigate whether the outcome of breast cancer (BC) patients treated with adjuvant chemotherapy is affected by co-mutated TP53 and PIK3CA according to stromal tumor-infiltrating lymphocytes ...

    • Frequency and predictors of chemotherapy-associated venous thromboembolism: The prospective PREVENT study 

      Kakkos S.K., Arnaoutoglou E., Tsolakis I.A., Giannoukas A., Papadimitriou C.A., Kentepozidis N., Boukovinas I., Kalofonos H.P., Labropoulos N., Matsagkas M. (2020)
      Background: Our knowledge on the burden of symptomatic and asymptomatic venous thromboembolism (VTE) in patients with cancer undergoing chemotherapy is limited. The aim of our study was to prospectively investigate the ...

    • Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP 

      Vassilakopoulos T.P., Michail M., Papageorgiou S., Kourti G., Angelopoulou M.K., Panitsas F., Sachanas S., Kalpadakis C., Katodritou E., Leonidopoulou T., Kotsianidis I., Hatzimichael E., Kotsopoulou M., Dimou M., Variamis E., Boutsis D., Terpos E., Dimopoulou M.N., Karakatsanis S., Michalis E., Karianakis G., Tsirkinidis P., Vadikolia C., Poziopoulos C., Pigaditou A., Vrakidou E., Economopoulos T., Kyriazopoulou L., Siakantaris M.P., Kyrtsonis M.-C., Symeonidis A., Anargyrou K., Papaioannou M., Hatjiharissi E., Vervessou E., Tsirogianni M., Palassopoulou M., Gainaru G., Stefanoudaki E., Zikos P., Tsirigotis P., Tsourouflis G., Assimakopoulou T., Konstantinidou P., A. Papadaki H., Megalakaki K., Dimopoulos M.-A., Pappa V., Karmiris T., Roussou P., Panayiotidis P., Konstantopoulos K., Pangalis G.A. (2021)
      Background: R-CHOP can cure approximately 75% of patients with primary mediastinal large B-cell lymphoma (PMLBCL), but prognostic factors have not been sufficiently evaluated yet. R-da- EPOCH is potentially more effective ...

    • Medical management of gastric cancer: a 2017 update 

      Charalampakis N., Economopoulou P., Kotsantis I., Tolia M., Schizas D., Liakakos T., Elimova E., Ajani J.A., Psyrri A. (2018)
      Gastric cancer remains a considerable health burden throughout the world. The Cancer Genome Atlas (TCGA) analysis has recently unveiled 4 genotypes of gastric cancer with data not ready to change treatment strategy yet. A ...

    • Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies 

      Vassilakopoulos T.P., Papageorgiou S.G., Angelopoulou M.K., Chatziioannou S., Prassopoulos V., Karakatsanis S., Arapaki M., Mellios Z., Sachanas S., Kalpadakis C., Katodritou E., Leonidopoulou T., Kotsianidis I., Hatzimichael E., Kotsopoulou M., Dimou M., Variamis E., Boutsis D., Terpos E., Michali E., Karianakis G., Tsirkinidis P., Vadikolia C., Poziopoulos C., Pigaditou A., Vrakidou E., Siakantaris M.P., Kyrtsonis M.-C., Symeonidis A., Anargyrou K., Papaioannou M., Chatziharissi E., Vervessou E., Tsirogianni M., Palassopoulou M., Gainaru G., Mainta C., Tsirigotis P., Assimakopoulou T., Konstantinidou P., Papadaki H., Dimopoulos M.-A., Pappa V., Karmiris T., Roussou P., Datseris I., Panayiotidis P., Konstantopoulos K., Pangalis G.A., Rondogianni P. (2021)
      End-of-treatment (EoT) PET/CT is used as a guide to omit radiotherapy (RT) patients with primary mediastinal large B-cell lymphoma (PMBCL). We present the mature and extended results of a retrospective study evaluating the ...

    • Primary extranodal non Hodgkin's lymphoma of the head and neck in adults: A clinicopathological comparison between tonsillar and non tonsillar lymphomas 

      Economopoulos, T.; Fountzilas, G.; Kostourou, A.; Daniilidis, J.; Pavlidis, N.; Andreopoulou, H.; Nicolaou, A.; Papageorgiou, E.; Mellou, S.; Dervenoulas, J.; Stathakis, N. (1998)
      Primary extranodal NHL of the head and neck (HN-NHL) accounts for 10-20% of all cases of NHL. Despite their frequency, the natural history and biological behaviour of these lymphomas is poorly understood. In this study we ...

    • Primary retroperitoneal non-Hodgkin lymphoma presenting with torturous generalized pruritus in an elderly 

      Daponte, A.; Ioannou, M.; Gioti, C.; Kallitsaris, A.; Dalekos, G. N.; Messinis, I. E. (2007)
      Introduction: A case of a rare primary retroperitoneal non-Hodgkin lymphoma (NHL), which presented with torturous generalized pruritus in a 74-year-old female patient is reported Methods: Case report. Results: Explorative ...

    • Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma 

      Karakatsanis S.J., Bouzani M., Symeonidis A., Angelopoulou M.K., Papageorgiou S.G., Michail M., Gainaru G., Kourti G., sachanas S., Kalpadakis C., Katodritou E., Leonidopoulou T., Kotsianidis I., Hatzimichael E., Kotsopoulou M., Dimou M., Variamis E., Boutsis D., Kanellias N., Dimopoulou M.N., Michali E., Karianakis G., Tsirkinidis P., Vadikolia C., Poziopoulos C., Pigaditou A., Vrakidou E., Economopoulos T., Kyriazopoulou L., Siakantaris M.P., Kyrtsonis M.-C., Anargyrou K., Papaioannou M., Hatjiharissi E., Vervessou E., Tsirogianni M., Palassopoulou M., Stefanoudaki E., Zikos P., Tsirigotis P., Tsourouflis G., Assimakopoulou T., Verrou E., Papadaki H., Lampropoulou P., Dimopoulos M.-A., Pappa V., Konstantopoulos K., Karmiris T., Roussou P., Panayiotidis P., Pangalis G.A., Vassilakopoulos T.P. (2022)
      Background/Aim: Primary mediastinal large Bcell lymphoma (PMLBCL) is an aggressive B-cell non- Hodgkin lymphoma (NHL), whose prognosis has greatly improved since the incorporation of the anti-CD20 monoclonal antibody ...

    • Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival 

      Katodritou E., Kyrtsonis M.-C., Delimpasi S., Kyriakou D., Symeonidis A., Spanoudakis E., Vasilopoulos G., Anagnostopoulos A., Kioumi A., Zikos P., Aktypi A., Briasoulis E., Megalakaki A., Repousis P., Adamopoulos I., Gogos D., Kotsopoulou M., Pappa V., Papadaki E., Fotiou D., Nikolaou E., Giannopoulou E., Hatzimichael E., Giannakoulas N., Douka V., Kokoviadou K., Timotheatou D., Terpos E. (2018)
      We evaluated progression-free survival (PFS) rate of patients treated with lenalidomide/dexamethasone (Len/Dex), the efficacy of the combination, and the prognostic significance of treatment at biochemical vs. clinical ...

    • Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG) 

      Koutsoukos K., Tzannis K., Christodoulou C., Karavasilis V., Bakoyiannis C., Makatsoris T., Papandreou C.N., Pectasides D., Dimopoulos M.A., Bamias A. (2016)
      Purpose: Following the establishment of adjuvant carboplatin in stage I testicular seminoma as a standard, we adopted this treatment for all stage I seminoma patients. We report our 8-year experience and compare these ...